Oscotec Inc.

NEWSROOM

Notice Press Releases Publications IR Materials

Home NEWSROOM Press Releases

TDefault

✔ Go Website with Viewer Search Write

Korea`s Yuhan Licenses out Lung Cancer Treatment to Janssen Biotech

Date2018-11-05 MediaBusinessKorea PipelineLazertinib

Read More
Janssen Announces Phase 1 Results for Bispecific Antibody Amivantamab in the treatment of Patients with Advanced Non-Small Cell Lung Cancer Harboring Exon 20 Insertion Mutations

Date2020-05-18 MediaBioSpace PipelineLazertinib

Read More
IPOs spawn instant billionaires

Date2007-02-20 MediaThe Korea Herald PipelineOscotec

Read More
INTERVIEW: Oscotec Lays Out Global Ambitions For RA, Cancer Drugs

Date2016-08-23 MediaScrip (Informa Pharma Intelligence) PipelineOscotec

Read More
Genosco/Yuhan Announce Results from Phase 1/2 Study of YH25448, a 3rd-Generation EGFR-TKI, in Advanced NSCLC to be Presented at ASCO 2018

Date2018-05-16 MediaBusinesswire PipelineLazertinib

Read More
Genosco gears up for IPO

Date2019-01-28 MediaTHE INVESTOR PipelineGenosco

Read More
G-749, a novel FLT3 Kinase inhibitor, can overcome drug resistance for the treatment of acute myeloid leukemia.

Date2014-04-03 MediaPubMed PipelineSKI-G-801

Read More
AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications

Date2019-11-04 MediaMolecular Cancer PipelineSKI-G-801

Read More
Abstract 2010 : SKI-G-801, an AXL kinase inhibitor, blocks metastasis and induces anti-tumor immune response in various syngeneic cancer models

Date2019-07-01 MediaCANCER RESEARCH PipelineSKI-G-801

Read More
"Global Immune Thrombocytopenia (ITP) Market Insights, Epidemiology, and Forecasts, 2017-2028 : Focus on United States, Germany, Spain, Italy, France, and the United Kingdom, and Japan"

Date2019-12-02 MediaPRNewswire PipelineGenosco

Read More
"ASCO 2018: Genosco/Yuhan Announce Results from Phase 1/2 Study of Lazertinib (YH25448, GNS-1480), a 3rd-Generation EGFR-TKI, in Advanced NSCLC"

Date2018-06-03 MediaBusinesswire PipelineLazertinib

Read More

주주님들께 드리는 글	2022.08.30
SCI Journal - SKI-G-8...	2022.02.16
FLT3/AXL Inhibitor (A...	2020.06.22

Translating science into medicine

PRESS

NEWSROOM

Korea`s Yuhan Licenses out Lung Cancer Treatment to Janssen Biotech

Janssen Announces Phase 1 Results for Bispecific Antibody Amivantamab in the treatment of Patients with Advanced Non-Small Cell Lung Cancer Harboring Exon 20 Insertion Mutations

IPOs spawn instant billionaires

INTERVIEW: Oscotec Lays Out Global Ambitions For RA, Cancer Drugs

Genosco/Yuhan Announce Results from Phase 1/2 Study of YH25448, a 3rd-Generation EGFR-TKI, in Advanced NSCLC to be Presented at ASCO 2018

Genosco gears up for IPO

G-749, a novel FLT3 Kinase inhibitor, can overcome drug resistance for the treatment of acute myeloid leukemia.

AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications

Abstract 2010 : SKI-G-801, an AXL kinase inhibitor, blocks metastasis and induces anti-tumor immune response in various syngeneic cancer models

"Global Immune Thrombocytopenia (ITP) Market Insights, Epidemiology, and Forecasts, 2017-2028 : Focus on United States, Germany, Spain, Italy, France, and the United Kingdom, and Japan"

"ASCO 2018: Genosco/Yuhan Announce Results from Phase 1/2 Study of Lazertinib (YH25448, GNS-1480), a 3rd-Generation EGFR-TKI, in Advanced NSCLC"

To inquire